Case Study | September 08, 2014

Toshiba’s Infinix-i Cardiovascular X-ray Ushers in a New Era of Cost-Effective Disease Treatment

PinnacleHealth developed a successful TAVR program based on the heart team approach and the advanced hybrid OR imaging technology

Infinix-i, TAVR, TOSHIBA

The flexible design of the Infinix-i streamlines procedures and allows operators to obtain a wide range of imaging angles without repositioning the patient.

Brijeshwar Maini, M.D., director of advanced cardiac and endovascular interventional laboratory, director of cardiovascular research and education and medical director of the PinnacleHealth CVI Valve Clinic

After several years of trials and increasing clinical use, transcatheter aortic valve replacement (TAVR) has reached a tipping point. It is quickly becoming the standard of care for ill patients suffering from aortic valve stenosis who are not eligible for open heart surgery. Implemented successfully, TAVR procedures improve outcomes and quality of life for patients while reducing costs for hospitals. 

 

To get different clinical disciplines working together, PinnacleHealth created a “heart team” that connects the knowledge base of cardiologists and interventionalists with the expertise of surgeons. As the team worked together and continued to become more familiar with each other and the procedure, the results naturally improved. A by-product of the team’s success was that procedure volumes also increased as the team received more referrals.

For hospitals that are able to push the envelope and innovate with cutting-edge treatments like TAVR, the economic benefits today can be attainable and quantified. 
 
“When TAVR was in its infancy, we developed the relationship between the surgical and percutaneous expertise of our clinicians,” said Brijeshwar Maini, M.D., director of advanced cardiac and endovascular interventional laboratory, director of cardiovascular research and education and medical director of the PinnacleHealth CVI Valve Clinic. “This collaboration enabled us to explore innovative ways to improve patient outcomes with more efficiency.” 
 
The Right Technology 
For its imaging system, PinnacleHealth selected Toshiba’s Infinix-i cardiovascular system for its hybrid OR lab, providing the versatility needed for innovative procedures and dose management optimizing tools for longer procedures. The system offers a mechanical design to provide excellent access and coverage. Its flexible C-arm movement and high-resolution images at various angles enable physicians to conduct advanced TAVR procedures with maximum efficacy. 
 
“The system’s flexible design streamlines procedures, allowing us to obtain a wide range of imaging angles without repositioning the patient,” Maini said. “The Infinix-i, combined with the OR table, produces a hybrid lab that is ready for today’s exams and tomorrow’s innovations.” 
 
State-of-the-art 3mensio and CAAS software are also integrated into the system, making TAVR planning and real-time deployment even more accurate and efficient. 
 
As one of the finest TAVR programs available today, PinnacleHealth has leveraged its heart team approach and the latest technology to achieve fewer readmissions and lower costs.
 
The Business Case for TAVR 
There is often a misconception that newer procedures are more expensive and result in a greater burden for the healthcare system. For TAVR programs, the opposite is true, as these procedures can help reduce readmissions of heart failure patients who are the sickest and most vulnerable to long medical stays. 
 
“For hospitals that are able to push the envelope and innovate with cutting-edge treatments like TAVR, the economic benefits are tangible and quantifiable,” Maini said. 
 
The growth in TAVR procedures and the ability to conduct them with the latest in imaging technology is bringing less invasive, more efficient and lower cost treatments to both patients and healthcare providers.
 

Keys to Developing a Successful TAVR Program:

• Developing the Right Lab: The most important decision for a TAVR program is designing the right lab. Toshiba’s Infinix-i cardiovascular system provides unmatched flexibility in system design and configurations to meet clinicians’ needs to conduct these procedures with ease. 

• Improving Patient Care: Combining long-term strategy and
collaborative planning with innovative, flexible technology can have
a very positive impact on patient care and results. 

• Economic Upside: TAVR programs can help reduce readmissions of heart failure patients. Implemented and managed well, a TAVR program should save hospitals money.

For more information: www.medical.toshiba.com

Related Content

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation. #COVID19 #coronavirus

The Edwards Lifesciences Cardioband for tricuspid valve regurgitation is one of the device trials being paused for the duration of the COVID-19 outbreak.

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Edwards Lifesciences Corp.
Conclusions from the TAVR vs surgery trial for aortic valve replacement in the U.K. presented by William D. Toff, M.D. at ACC 20. #ACC20 #ACC2020 #TAVR #TAVR

Conclusions from the real world TAVR vs. surgery trial for aortic valve replacement outcomes in the U.K., presented by William D. Toff, M.D. at ACC 20. 

News | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients in the United Kingdom (U.K.) who underwent transcatheter aortic valve replacement (TAVR) di
PARTNER 3 trial shows positive results for Sapien 3 in low-risk surgical patients. #ACC20 #ACC2020 #Sapien3 #TAVR
Feature | Heart Valve Technology | March 30, 2020
March 30, 2020 — Patients undergoing transcatheter aortic valve repair (TAVR) low-risk patients at two years did just
News | Heart Valve Technology | March 29, 2020
March 29, 2020 — Worse than expected outcomes were found for survival and quality of life among patients undergoing t
Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replacement (TAVR) procedures had a high rate of success and low risk of death or disabling stroke at 30 days, according to new data presented at the American College of Cardiology (ACC) 2020 Scientific Session. #ACC20 #ACC2020
Feature | Heart Valve Technology | March 29, 2020 | Dave Fornell, Editor
March 29, 2020 — Patients with bicuspid, or two-leaflet, aortic valves who undergo transcatheter aortic valve replace
The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

The heart team at St. James University Hospital Dublin was the first to perform a human implant of the CroiValve Duo Tricuspid Coaptation Valve technology for tricuspid repair.  

News | Heart Valve Technology | March 25, 2020
 
A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Imagine courtesy of TeraRecon. #TAVR #TAVI

A 3-D reconstruction of a cardiac CT scan showing an implanted Medtronic CoreValve TAVR device. Image courtesy of TeraRecon

Feature | Heart Valve Technology | February 24, 2020 | Dave Fornell, Editor
In August 2019, the U.S.
Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive heart valve replacement to open-heart surgery. Photo by Cedars-Sinai. TAVR performs as well as surgery for aortic valve replacement.

Raj Makkar, M.D., led a multicenter national study comparing outcomes for minimally invasive TAVR heart valve replacement to open-heart surgery. The study showed the two methods have similar outcomes. Photo by Cedars-Sinai.

News | Heart Valve Technology | January 31, 2020
January 31, 2020 — A new study from the Sm...
Abbott Tendyne TMVR, TMVI system received European CE mark clearance in January 2020. The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. Prevents LVOT obstruction.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system uses an anchor attached to the apex of the heart with a whether line attached to the valve. This helps to keep the valve anchored in the mitral annulus and prevent embolization. This anchor system was used because, unlike the aortic valve, the mitral valve has a very thin landing zone to secure the valve. The design also eliminated any hardware hanging or folding into the left ventricle, which could cause left ventricular outflow track (LVOT) obstruction, which can prevent blood flow through the aortic valve and to the rest of the body.

Feature | Heart Valve Technology | January 30, 2020
January 30, 2020 — The Abbott Tendyne Transcatheter Mitral Valve Implantation (TMVI) system received European CE mark
Overlay Init